Capital 2B, Info Edge, and Temasek back the seed round to boost modular factory innovation
Deeptech manufacturing startup Leumas has raised $2.2 million in a seed funding round led by Capital 2B, a fund backed by Info Edge and Temasek. The round also saw participation from Capital-A and Anicut Capital, reflecting growing investor confidence in Leumas’s disruptive factory-as-a-service model.
Funding to Fuel R&D and Factory Pilots
Leumas stated that the newly secured funds will be utilized to strengthen its research and development, scale its on-demand manufacturing infrastructure, and deploy pilot modular factories for pharma and wellness brands.
The startup is pioneering a software-defined, robot-driven production system that allows brands to manufacture products quickly, cost-efficiently, and at scale, without compromising on compliance or quality.
A Cyber-Physical Revolution in Manufacturing
Founded in 2016 by Subhajit Biswas and Nitesh Kumar, Leumas is redefining contract manufacturing through its factory-as-a-service (FaaS) model. The startup’s core innovation lies in cyber-physical production technology, a modular system that uses AI-powered robotics, vision-based quality control, and autonomous operations.
This system allows companies to rapidly transition from prototype to full-scale production, minimizing lead times, reducing capital expenditure, and maintaining product quality across geographies.
Market Opportunity: A $400 Billion Future
According to industry research, the outsourced pharma and wellness manufacturing market is poised to exceed $400 billion by 2030. The global wellness economy, including personal care, nutrition, fitness, and preventive health, is already valued at over $1.5 trillion, growing at a 5-10% annual rate.
India’s pharmaceutical industry also continues to surge. The market touched $50 billion in FY2024 and is projected to cross $130 billion by 2030, driven by exports, generics, and innovation in drug delivery and production methods.
Also Read: Machaxi Secures $1.5 Million in Funding Led by Rainmatter and Prakash Padukone
Traction with Wellness and Pharma Brands
In the past 12 months, Leumas has:
- Co-developed modular manufacturing lines with leading wellness brands
- Enabled production of over 120 products across India, the US, and the MENA region
- Partnered with pharma and food-tech research institutes to build dedicated modular factory units
These milestones position Leumas as a first mover in combining modularity and AI-led robotics for small-batch and compliant manufacturing needs.
Backed by Deeptech-Focused Investors
Capital 2B, the head investor in this round, is known for investing in technology companies that have a mesh of hardware innovation with software that can scale. The fund, which is supported by Info Edge and Temasek, believes that Leumas will be the company to revolutionise industrial operations in the healthcare economy.
Capital-A, which previously invested in Leumas’s ₹7 crore pre-seed round, returned for this round, reaffirming its belief in the startup’s futuristic approach to agile, software-driven production systems.
A New Era of Factory-as-a-Service
Leumas’s nano-factories are built to enable rapid product launches, especially for D2C wellness brands and specialty pharma products, where speed-to-market and batch-level customization are crucial.
“Our modular factories remove bottlenecks, lower risks, and help our clients go from R&D to revenue faster than ever,” said Subhajit Biswas, Co-founder and CEO of Leumas. “This funding enables us to deepen our tech stack and scale our pilot deployments across India and globally.”
Looking Ahead
With this funding, Leumas aims to:
- Expand its R&D team to improve autonomous systems, robotics, and software intelligence
- Launch pilot deployments of nano-factories for partner brands and research institutes
- Scale manufacturing operations to support rapid product iterations in pharma and wellness
As the demand for flexible, small-scale, compliant production grows worldwide, Leumas is uniquely positioned to lead the next phase of industrial transformation.
Conclusion
Leumas’s $2.2 million seed round marks a significant milestone in India’s deeptech landscape. By fusing automation, AI, and modular engineering, the startup is creating a bold, scalable solution for the global pharmaceutical and wellness manufacturing sectors. With investor backing and early traction already in place, Leumas is set to redefine how the world thinks about manufacturing agility, precision, and compliance.
Also Read: Garuda Aerospace Raises $1 Million from Narotam Sekhsaria’s Family Office and Others
